Mezzion Pharma, previously known as Dong-A Pharmtech (a former subsidiary of Dong-A Socio Holdings), is a biotech company focused on the development of drugs for multiple diseases, including erectile dysfunction, prostatic hyperplasia, hypertension and pulmonary arterial hypertension.The company is headquartered in Korea.In January 2017, Mezzion had filed a suit for damages against Dr Reddy's in New Jersey State court alleging that Dr Reddy's committed fraud relating to Dr Reddy's hiding significant deficiencies in its FDA cGMP practices, and misrepresenting its compliance to Mezzion. The suit notes that Dr Reddy's repeatedly represented to Mezzion that it was compliant with FDA regulations, and that it hid its misconduct from Mezzion. The suit also states that Dr Reddy's misconduct was the sole reason given by the FDA to deny approval of Mezzion's NDA for udenafil for the treatment of erectile dysfunction and for FDA's refusal to grant marketing approval of Mezzion's udenafil finished drug product. As a